Tomorrow's Science For Today's Clinician
GSK and Vir Biotechnology claimed that preclinical data showed the drug retains activity against key mutations of the new Omicron variant of coronavirus.
Five Indian drugmakers, including Cipla, Dr Reddy’s Laboratories, Sun Pharmaceutical Industries, Torrent Pharmaceuticals and Emcure Pharma, had early this year signed separate non-exclusive voluntary licensing agreements with the inventor Merck Sharp & Dohme (MSD) for manufacturing and marketing this drug locally.
As per the approval, the patient can start taking the medicine within five days of the symptom onset. Molnupiravir, is the first oral anti-viral drug that patients could take at home to ease symptoms and speed up recovery.
With this launch, the company aims to improve patient access to SGLT2 inhibitors and DPP4 inhibitors which have proven benefits in the effective management of diabetes with added advantage of patient compliance.
Results showed no new safety signals or concerns with the use of favipiravir, and already-known side effects such as weakness, gastritis, diarrhea, vomiting, etc., were found to be mild in nature. The time for fever resolution was 4 days, while the time for a clinical cure was 7 days.
Merck Specialties Pvt ltd launched Pergoveris Pen for advanced infertility treatment in India.
The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the application for orphan drug designation for AK-OTOF, a gene therapy intended for the treatment of otoferlin gene-mediated hearing loss, Akouos, Inc announced.
Supernus Pharmaceuticals announced that the US FDA approved viloxazine extended-release capsules (Qelbree) for the treatment of attention-deficit hyperactivity disorder (ADHD) in paediatric patients 6 to 17 years of age.
Bristol Myers Squibb announced that the European Commission (EC) has approved ozanimod (Zeposia) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease.
EigerBio Pharmaceuticals Inc announced that the US FDA accepted the New Drug Application (NDA) for accelerated review of lonafarnib (Zokinvy) for the treatment of progeria and progeroid laminopathies.